|
|
|
18.11.26 - 18:03
|
Biocom Welcomes Zachary Hornby of Callio Therapeutics and Kevin Marks of Parker Institute to Board of Directors (Business Wire)
|
|
|
SOUTH SAN FRANCISCO, Calif. & LOS ANGELES & SAN DIEGO--(BUSINESS WIRE)--#boardofdirectors--Biocom, the largest life science membership association, representing companies across California and major life science markets worldwide, today announced the appointment of Zachary Hornby, chief executive officer of Callio Therapeutics, and Kevin Marks, chief legal officer of Parker Institute to its board of directors.“Zach and Kevin have each helped turn breakthrough science into real companies and real treatments, and they are exactly the kind of leaders Biocom needs at a pivotal moment for our industry,” said Tim Scott, president and CEO of Biocom. “Zach has taken companies from the lab to the public markets and helped lead Ignyta's $2 billion sale to Roche, while Kevin has spent decades guiding legal strategy across diagnostics, regenerative medicine and immunotherapy. Their judgment will sharpen how we serve our members as we grow across life science markets. We're fortunate to have them on our board....
|
|
|
|
|
|
|
17.11.26 - 20:12
|
Roche Underperform (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat Roche nach einem Gespräch mit Finanzchef Alan Hippe einer hauseigenen Branchenkonferenz auf "Underperform" mit einem Kursziel von 250 Franken belassen. Dieser habe sich erfreut über die Giredestrant-Zulassung ......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17.11.26 - 08:36
|
Roche Outperform (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Roche auf "Outperform" mit einem Kursziel von 400 Franken belassen. Trung Huynh sieht die überraschend frühe Zulassung von Giredestrant in Brustkrebs-Kombinationstherapie positiv ......
|
|
|
|
|
|
|
16.11.26 - 23:18
|
FDA approves Roche′s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer (GlobeNewswire EN)
|
|
|
Basel, 16 November 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Wilserdly™ (giredestrant) in combination with everolimus for the treatment of adults with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated locally advanced or metastatic breast cancer, as detected by an FDA-authorised test, whose disease has recurred during or after completion of endocrine-based adjuvant therapy, or has progressed on at least one endocrine-based regimen in the metastatic setting....
|
|
|
|